Hutch News Stories

Fred Hutch President and Director Dr. Gary Gilliland announces plan to step down

5 years of leadership reinforced Fred Hutch scientific excellence, collaborative research, partnerships and financial strength
Photo of Gary Gilliland speaking at a podium. Behind him is a large-screen video projection of him speaking.
On Tuesday, Fred Hutch President and Director Dr. Gary Gilliland announced his plan to step down in 2020. In this photo, taken on June 30, 2015, Gilliland speaks at the Life Science Innovation Northwest Conference in Seattle six months after he took the helm of the Hutch. Photo by Robert Hood / Fred Hutch News Service

Dr. D. Gary Gilliland, president and director of Fred Hutchinson Cancer Research Center, announced Tuesday his plans to step down in 2020.

His accomplishments during his time at the helm of Fred Hutch are numerous, say Fred Hutch board leaders, and he leaves the Hutch in a strong position for the future. Since 2015, the center has grown and diversified its faculty, increased its already-strong federal grant funding, quadrupled its endowment, and forged new internal and external research collaborations, among other achievements.

Gilliland, who has been serving in this role since January 2015, will continue leading the Hutch during the search for his successor, which is moving forward under the leadership of a diverse search committee that includes trustees, faculty and administrative leaders. Gilliland will become president and director emeritus after ensuring a smooth transition to the new leader.

“Gary has had incredible achievements in setting the Hutch’s strategy, growing our teams and expanding our resources,” said Matthew McIlwain, chair of the Fred Hutch board of trustees. “Although the board hoped Gary could remain center director longer, we understand his decision and are confident in the strengths of our faculty, staff and leadership teams across both science and administration. Gary has done an outstanding job of advancing our mission and preparing Fred Hutch for the opportunities ahead, and we are delighted that he will remain affiliated with the organization.”

Most important, thanks to Gilliland’s leadership, Hutch scientists are well-positioned to continue making the lifesaving discoveries for which the center is known worldwide, said Kathy Surace-Smith, who will chair the board of trustees beginning in June 2020.

“Gary has really set the stage for the Hutch’s future,” Surace-Smith said. “Throughout his time as president and director, Hutch scientists have made extraordinary discoveries in cutting-edge fields as diverse as cancer immunotherapy and data science. Thanks to his outstanding leadership and vision, the Hutch’s top-notch researchers have the resources and infrastructure they need to continue doing what they do best for years to come.”

Composite image: Left, photo of Joe Biden speaking to Gary Gilliland at a panel discussion. Fred Hutch logos are visibile in the background. On the right, a portrait of Kathy Surace-Smith
Left: Former Vice President Joe Biden, right, speaks with Dr. Gary Gilliland at an event at Fred Hutch on March 21, 2016, during Biden's Cancer Moonshot listening tour. Right: Kathy Surace-Smith, vice-chair of the Fred Hutch board of trustees Photos by Robert Hood / Fred Hutch News Service

Hutch leadership capstones Gilliland’s accomplished career

Gilliland, a blood cancer physician-scientist by training, is the fifth Fred Hutch president and director since the center opened its doors in 1975.

Before his arrival to the Hutch, Gilliland had built a global reputation for his seminal scientific discoveries in leukemia biology at Harvard Medical School and for his leadership in academia and industry. Among his past leadership roles, Gilliland was director of the leukemia program at the Dana-Farber/Harvard Cancer Center, a senior vice president and global oncology franchise head at Merck & Co., and a vice dean and vice president of precision medicine at Perelman School of Medicine at the University of Pennsylvania. He has earned numerous prestigious awards and honors for his work.

Being chosen to lead Fred Hutch was, for Gilliland, a culmination of that long and distinguished career — “like coming home,” he said in a November 2014 profile when the Hutch announced his hire. “Everything I’ve done in my career has pointed here.”

In a message to Fred Hutch employees announcing his decision, Gilliland said, “Leading Fred Hutch has been the high point of my career.”

“The center is in an excellent position, and I am confident that now is the right time to open the door for that new leader,” Gilliland wrote.

Gilliland was preceded as Fred Hutch president and director by Dr. Lawrence Corey, Nobel laureate Dr. Lee Hartwell, the late Dr. Robert Day, and the late Fred Hutch founder Dr. William Hutchinson.

Photo of three men standing side by side in a hallway
Fred Hutch President and Director Dr. Gary Gilliland with predecessors Drs. Larry Corey (middle) and Lee Hartwell in Fred Hutch's Thomas Building in January 2018. Photo by Robert Hood / Fred Hutch News Service

Under Gilliland’s leadership, Hutch's scientific strength reinforced

As president and director, Gilliland’s responsibilities have included setting the strategic direction of Fred Hutch and overseeing centerwide initiatives. He also directs the Fred Hutch/University of Washington Cancer Consortium, which includes the Hutch, the UW schools of Medicine and Public Health, Seattle Cancer Care Alliance and Seattle Children’s.

In these roles, Gilliland has sought to reinforce the Hutch’s longstanding commitment to scientific excellence, Surace-Smith said.

“The Hutch’s culture of high-quality, bold research — all aimed at improving and saving lives — is what makes this institution stand out,” she said. “In all of Gary’s leadership initiatives at the Hutch, he’s been guided by the question: ‘How can we advance the best research to help patients?’”

One way Gilliland has done so is by forging connections between researchers in different disciplines. Among Gilliland’s major initiatives was the creation of the Hutch’s Integrated Research Centers, or IRCs, which promote collaboration among researchers across campus and throughout the Consortium on high-impact, innovative projects. The Hutch currently has three IRCs, which focus on immunotherapy, pathogen-associated cancers and data science. 

Photo of Dr. Gary Gilliland in front of a screen projecting the words: Immunotherapy Integrated Research Center, in collaboration with CCSG Program in Cancer Immunology, Faculty Retreat, January 12, 2018
Under Dr. Gary Gilliland's leadership, Fred Hutch launched new initiatives for collaborative science, such as the Immunotherapy Integrated Research Center. Photo by Robert Hood / Fred Hutch News Service

The creation of new infrastructure and resources to advance cancer immunotherapy research has been a particular area of emphasis during Gilliland’s tenure at the Hutch. A notable example is 2016’s opening of the Bezos Family Immunotherapy Clinic at SCCA, a facility on the Hutch campus dedicated to providing immunotherapies to cancer patients on clinical trials and enabling research to make these strategies work better for more patients.

Gilliland also was instrumental in catalyzing the Hutch’s lease of Seattle’s historic Lake Union Steam Plant, which the Hutch is now remodeling to advance, in particular, high-impact research at the intersection of immunology, data science and computational biology.

Fred Hutch Chief Operating Officer Steve Stadum has partnered closely with Gilliland on Steam Plant and other scientific and administrative initiatives to advance Hutch science.

"The Steam Plant project, and the science it will enable, is just one example of Gary’s ability to be opportunistic and act with urgency in a way that is consistent with the center’s goals and where the cutting edge of science is headed in the next five, 10, 20 years or more," Stadum said. "And he has a gift for bringing people together to do more collaboratively than they could alone."

Photo of a line of people cutting a ceremonial green ribbon. Behind them, the words "Bezos Family Immunotherapy Clinic" are mounted on the wall.
Lymphoma patient and immunotherapy recipient Stephanie Florence of Lewiston, Idaho, performs the ceremonial ribbon cutting at the new Bezos Family Immunotherapy Clinic at Seattle Cancer Care Alliance on the Fred Hutch campus on Dec. 12, 2016. Among those with Florence are Dr. Gary Gilliland (far right), Hutch researchers, members of the Bezos family and Hutch trustees. Photo by Robert Hood / Fred Hutch News Service

Strengthening science through diversity, teamwork

For years, Fred Hutch has consistently received more funding from the National Institutes of Health than any other research organization of its type. That strength has grown under Gilliland, who has overseen a 48% increase the institution’s grant funding and hired dozens of new faculty members.

Meanwhile, Gilliland has set the Hutch on a course of diversifying its funding sources and enhancing the center’s relationships with industry and other outside collaborators.

“In this way, Gary has helped us to invest in world-class investigators, modern facilities and innovative team research — enabling science far into the future,” McIlwain said. “This has also helped Hutch scientists translate discoveries to patients more rapidly and advance their research in powerful new ways, thanks to new-found synergies with tech companies and other nontraditional collaborators.”

Under Gilliland’s leadership, there has been significant growth in the Hutch’s endowment, which is critical since endowments represent a sustainable, dependable resource for funding future breakthroughs.

The center also now has 27 endowed faculty chairs, compared to three when Gilliland joined the Hutch. Endowed chairs help recruit and retain the best scientific talent, and they provide those scientists with the long-term sustainable funding and freedom they need to take potentially high-impact risks. Gilliland has ensured gender parity in these chairs as part of his commitment to advancing Hutch research by promoting diversity and inclusion in science and leadership. 

Composite photo: Image 1: Photo of Matt McIlwain. Image 2: Photo of Gary Gilliland seated at a table with Madame Peng and Bill Gates.
Left: Matthew McIlwain, chair of the Fred Hutch board of trustees, speaks at the 2018 Fred Hutch Holiday Gala. Right: Madame Peng Liyuan, the wife of Chinese President Xi Jinping, speaks with Dr. Gary Gilliland and Bill Gates at Fred Hutch on Sept. 23, 2015. Photos by Robert Hood / Fred Hutch News Service

The scientific teams that Gilliland has helped to build and strengthen at Fred Hutch through these and other efforts will long outlast his tenure as president and director. Those teams’ accomplishments — whether made since 2015 or still to come — are a point of pride for Gilliland as he reflects on his time at the Hutch.

In his announcement to the Hutch community, Gilliland wrote that he was “proud of what we’ve accomplished together.”

But, he added, “I say ‘we’ because, ultimately, this organization’s success isn’t measured by the work of any one person.

“It is the result of the commitment and dedication of everyone here.” 

Photo taken through an open doorway shows Gary Gilliland from behind speaking to a gathered crowd of people on a deck.
Dr. Gary Gilliland welcomes Fred Hutch trustees to an event at the Steam Plant Building to celebrate nine new endowed chairs at Fred Hutch, among the more than two dozen new endowed chairs created during Gilliland's time as Hutch president and director. Photo by Robert Hood / Fred Hutch News Service

Susan Keown, a staff writer at Fred Hutchinson Cancer Research Center, has written about health and research topics for a variety of research institutions, including the National Institutes of Health and the Centers for Disease Control and Prevention. Reach her at skeown@fredhutch.org or on Twitter @sejkeown.

Are you interested in reprinting or republishing this story? Be our guest! We want to help connect people with the information they need. We just ask that you link back to the original article, preserve the author’s byline and refrain from making edits that alter the original context. Questions? Email us at communications@fredhutch.org

Help Us Eliminate Cancer

Your gift will be triple-matched, making three times the impact for lifesaving research.

Last Modified, October 28, 2019